Skip to Content

Grant Support

Alex's Lemonade Stand Foundation, "Identifying how Pre-existing Anti-Therapeutic Antibodies (PATA) are Associated with Better Outcome in a Clinical Trial of ADCC-inducing Anti-GD2 mAb" (2015-2017). Sondel, Principal Investigator

MACC Fund, "Enhancing Immunocytokine Efficacy in Neuroblastoma: Synergy with Radiation Therapy (RT) and Development of 2nd Generation Immunocytokines (IC)" (2015-2017). Sondel, Principal Investigator

St. Baldrick's, "The Effect of Radiation on Tumor Cell Immune Susceptibility," (2015). Sondel, Co-Principal Investigator

Neuroblastoma Tumor Escape Variants Modulate MHC Class I Expression in Response to NK- or T Cell- Mediated Immunotherapy

KIR-Incompatible Transplantation in Pediatric Osteosarcoma and Rhabdomyosarcoma

Clinical Development of HU14.18-IL2 Targeted Therapy

Antitumor Mechanisms of anti-CD40/CpG-activated Macrophages

The Role of KIR and FcR Genotype in the Efficacy of mAb and IL2 Immunotherapy

A Phase I Trial of the Humanized Anti-GD2 Antibody (HU14.18K322A) in Children and Adolescents with Neuroblastoma or Melanoma

A Safety/Feasibility Trial of the Addition of the Humanized Anti-GD2 Antibody (Hu14.18K322A) with and without Natural Killer Cells to chemotherapy in Children and Adolescents with Recurrent / Refractory Neuroblastoma

COG Immunotherapy

Cancer Center Pilot Grant

CD Sub Sangtae

CD Sub Sangtae 2


Last updated: 06/26/2015
webmaster [at] pediatrics [dot] wisc [dot] edu
Copyright © 2015 The Board of Regents of the University of Wisconsin System